• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ:NXLIW)

0.0138 UNCHANGED
Last Price Updated: 3:18 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nexalin Technology, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
December 02, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
November 18, 2025
Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin’s non-invasive therapy 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
November 13, 2025
Appointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC Device 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
November 05, 2025
This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
October 30, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
October 21, 2025
Three Independent Studies Published in “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with Consistent Cognitive and... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
October 13, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
October 10, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
October 08, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
September 25, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
August 25, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
August 01, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
May 28, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
May 13, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
May 01, 2025
Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
April 24, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
April 23, 2025
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
April 21, 2025
Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO Clarity™ neurostimulation device integrated... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
April 14, 2025
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
April 02, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
March 26, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
March 03, 2025
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
February 28, 2025
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
February 26, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
February 18, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
February 10, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
February 03, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
January 23, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
January 14, 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
December 23, 2024
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 
From Nexalin Technology, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap